Genetically engineered vaccines
Current Allergy and Asthma Reports, ISSN: 1529-7322, Vol: 5, Issue: 3, Page: 197-203
2005
- 15Citations
- 22Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations15
- Citation Indexes15
- 15
- CrossRef10
- Captures22
- Readers22
- 22
Review Description
The application of recombinant DNA technology to allergen research has provided the sequence information and genetic material to produce new types of allergy vaccines. One general strategy has been to use the knowledge to produce synthetic peptides that represent selected T-cell or B-cell epitopes. The production of genetically engineered allergens provides an alternative strategy to construct hypoallergenic vaccines, which can provide a better and less selected representation of the epitopes. Many strategies have been used to produce such hypoallergens, and their ability to reduce allergenicity has been amply demonstrated by skin and nasal provocation tests. The retention of T cell-stimulating activity has also been demonstrated, and a consistent feature of the vaccines has been, despite the reduced immunoglobulin E (IgE)-binding reactivity, the ability to induce anti-allergen IgG antibody. The lead hypoallergens have been polypeptide fragments and trimeric constructs of the birch allergen Bet v I. A clinical trial with these medicaments has shown the ability to modify IgE and IgG antibody production, skin test reactivity, and symptom scores. This is the first trial of a recombinant allergy vaccine, and it has set a benchmark for further studies. A new generation of hypoallergens is now being produced based on the detailed knowledge of the tertiary structures of the allergens and of the T-cell and B-cell epitopes. The modifications have been made to change the topography of the allergens while retaining a stable, folding structure. In the case of Bet v I, tertiary structures of hypoallergens have been determined. Structurally modeled hypoallergens have been produced for pollen, venom, food, and latex allergens, with promising characteristics from preclinical studies. Copyright © 2005 by Current Science Inc.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=20044391246&origin=inward; http://dx.doi.org/10.1007/s11882-005-0038-4; http://www.ncbi.nlm.nih.gov/pubmed/15842957; https://link.springer.com/10.1007/s11882-005-0038-4; http://www.springerlink.com/index/10.1007/s11882-005-0038-4; http://www.springerlink.com/index/pdf/10.1007/s11882-005-0038-4; https://dx.doi.org/10.1007/s11882-005-0038-4; https://link.springer.com/article/10.1007/s11882-005-0038-4; https://research-repository.uwa.edu.au/en/publications/824a9ba0-0767-4324-a08b-8d7ff4ebd39a; https://research-repository.uwa.edu.au/en/publications/genetically-engineered-vaccaines; https://research-repository.uwa.edu.au/en/publications/genetically-engineered-vaccaines(824a9ba0-0767-4324-a08b-8d7ff4ebd39a).html; http://link.springer.com/10.1007/s11882-005-0038-4; https://link.springer.com/content/pdf/10.1007%2Fs11882-005-0038-4.pdf; http://link.springer.com/article/10.1007%2Fs11882-005-0038-4; http://research-repository.uwa.edu.au/en/publications/genetically-engineered-vaccaines(824a9ba0-0767-4324-a08b-8d7ff4ebd39a).html
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know